The 10-second takeaway
For the quarter ended Dec. 31 (Q1), Female Health met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.
Margins grew across the board.
Female Health logged revenue of $9.9 million. The one analyst polled by S&P Capital IQ foresaw sales of $9.9 million on the same basis. GAAP reported sales were 15% higher than the prior-year quarter's $8.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.12. The one earnings estimate compiled by S&P Capital IQ forecast $0.11 per share. GAAP EPS of $0.12 for Q1 were 33% higher than the prior-year quarter's $0.09 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 60.2%, 210 basis points better than the prior-year quarter. Operating margin was 36.3%, 410 basis points better than the prior-year quarter. Net margin was 35.7%, 490 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $7.4 million. On the bottom line, the average EPS estimate is $0.07.
Next year's average estimate for revenue is $37.4 million. The average EPS estimate is $0.52.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 303 members out of 312 rating the stock outperform, and nine members rating it underperform. Among 61 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 61 give Female Health a green thumbs-up, and give it a red thumbs-down.
Looking for alternatives to Female Health? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Female Health to My Watchlist.